Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 26, 2026

Top Research Reports for Meta, Netflix & Pfizer

View original at finance.yahoo.com
Top Research Reports for Meta, Netflix & Pfizer Thursday, February 26, 2026 The Zacks Research Daily presents the best research output of our analyst team…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Pfizer expects its recently launched and acquired products and a strong pipeline to help revive top-line growth toward the end of the decade

    80% confidence
  • Flowers Foods fourth quarter total company volume declined 2.2%

    80% confidence
  • Netflix has about two hours of viewing per member per day

    80% confidence
  • Altigen's top five accounts represented 83% of sales

    80% confidence
  • Recommendation improvement drove 20% lift in time spent on Threads

    80% confidence
  • Instagram Reels had a strong fourth-quarter, with watch time up more than 30% year-over-year in the United States

    80% confidence
  • Facebook video time continued to grow double-digits year-over-year in the United States

    80% confidence
  • Meta Platforms now expects to invest significantly more over the next few years in developing more advanced models and the largest AI services in the world

    80% confidence
  • Meta's improved recommendation system is driving up user engagement

    80% confidence
  • 2026 guidance projects revenue growth of 12-14% for Netflix

    80% confidence
  • Monetization of AI services will take considerable time

    80% confidence
  • Netflix has set an ambitious target to double its revenues by 2030 and reach a $1 trillion market capitalization

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com